Novo Nordisk Sues Apotex to Block Generic Version of Rybelsus

Novo Nordisk Inc. asked a court to block Apotex Inc. from selling a generic version of the Rybelsus diabetes drug it says infringes ten patents, according to a federal lawsuit.

Apotex’s generic version of Rybelsus would infringe 10 patents Novo Nordisk owns for the semaglutide drug, according to the complaint filed Oct. 10 in the US District Court for the District of New Jersey. The patents are set to expire between 2030 and 2034, Bloomberg Law estimates.

Novo received written notice of Apotex’s abbreviated new drug application to the Food and Drug Administration in August, the complaint said.

Apotex didn’t ...